IndustryCompany release

Senseonics lifts 2026 revenue and gross margin guidance after strong third quarter

🇺🇸 Senseonics Holdings, Inc. (SENS) · Mon 09 Nov 2026

The Eversense 365 maker reported Q3 revenue of $19.6M, driven by US growth, and raised its full-year outlook to $68-70M.

Senseonics Holdings reported third quarter 2026 results on 9 November, with revenue of $19.6M. The company attributed the growth to US uptake of Eversense 365, its one-year implantable continuous glucose monitoring (CGM) system. The headline for the announcement put the revenue increase at roughly 140%.

Gross margin for the quarter was about 62%. The company reported a net loss of $32.7M for the period.

Senseonics raised its full-year revenue guidance to $68-70M and its gross margin guidance to above 60%. The summary provided does not give the earlier guidance ranges.

The company also flagged two pipeline and product milestones. It plans to launch integration of Eversense 365 with Beta Bionics' iLet system in the fourth quarter of 2026, and it has begun a first-in-human study of Freedom, its next-generation CGM.

What it means for your team

  • Market-access teams may want to track how US demand for a one-year implantable CGM develops, as the company ties its growth to Eversense 365.
  • The planned Q4 2026 integration with Beta Bionics' iLet system is relevant to teams following interoperability between CGMs and automated insulin delivery.
  • The first-in-human study of Freedom marks the start of clinical evaluation for the company's next-generation CGM; regulatory timelines have not been disclosed in the material available.
  • The company remains loss-making despite the higher revenue and margin guidance.

Company's press release (SEC filing): Senseonics Holdings, Inc. ↗

Article written by VigiEye from the official source (Senseonics Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →